Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISTARIL vs ADVIL ALLERGY SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
Anxiety and tension associated with psychoneurosis,Pruritus due to allergic conditions (e.g., urticaria, atopic dermatitis),Sedation prior to dental or surgical procedures,Nausea and vomiting (off-label)
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Primarily hepatic via CYP3A4 and CYP2D6; major metabolites include cetirizine.
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Highly protein-bound: approximately 89-93%, primarily to albumin.
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
Volume of distribution: 7-10 L/kg, indicating extensive tissue distribution.
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Oral: incomplete bioavailability due to first-pass metabolism, estimated at 40-60%; IM: nearly complete (85-100%).
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
No specific adjustment; use with caution in severe renal impairment due to potential accumulation of metabolites.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
Oral: 0.5-1 mg/kg every 4-6 hours; maximum 50 mg per dose (≤12 years); IM: 0.5-1 mg/kg every 4-6 hours.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Start at lower end of dosing range (e.g., 25 mg oral 3-4 times daily); monitor for sedation and anticholinergic effects.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
No FDA black box warning.
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
May cause QT prolongation; use with caution in patients with risk factors (e.g., electrolyte imbalance, concomitant QT-prolonging drugs),Sedation and impaired cognitive/motor function; avoid driving or hazardous activities,Anticholinergic effects (e.g., urinary retention, constipation); use cautiously in elderly or patients with prostatic hypertrophy,Respiratory depression with concurrent CNS depressants,Use in pregnancy: avoid especially during early pregnancy; may increase risk of fetal abnormalities
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
Hypersensitivity to hydroxyzine or any component,Early pregnancy (first trimester),Porphyria,Breastfeeding (use caution)
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
Alcohol increases sedation and CNS depression; avoid concurrent use. No significant food interactions, but take with food if GI upset occurs.
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
First trimester: Limited human data; animal studies suggest no major teratogenic risk; fetal harm cannot be ruled out. Second and third trimesters: Hydroxyzine may cause neonatal withdrawal symptoms (irritability, tremors) with chronic maternal use near term; no evidence of structural anomalies.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
Hydroxyzine is excreted in human milk; M/P ratio not established. Potential for adverse effects in infants (sedation, irritability). Use during breastfeeding only if clearly needed; monitor infant for drowsiness.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
No specific dose adjustments recommended in pregnancy; use lowest effective dose. Hydroxyzine may be less effective if used as an antiemetic due to altered clearance; consider alternative agents.
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
VISTARIL (hydroxyzine pamoate) is a first-generation antihistamine with anxiolytic and sedative properties. It is often used for preoperative sedation, pruritus, and anxiety. Onset of sedation is rapid (15-30 minutes) but duration is short (4-6 hours). It has anticholinergic effects; caution in elderly and patients with glaucoma or prostatic hypertrophy. Do not administer intra-arterially or subcutaneously (risk of hemolysis or tissue necrosis). It is not a controlled substance, but has abuse potential. May cause significant somnolence; advise against driving or operating machinery.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Take as prescribed; do not exceed recommended dose.,May cause drowsiness; avoid driving or heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of allergic reaction (rash, difficulty breathing) immediately.,Do not stop abruptly without consulting doctor.,Store at room temperature away from moisture and heat.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISTARIL vs ADVIL ALLERGY SINUS, answered by our medical review team.
VISTARIL is a Antihistamine that works by Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.. ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISTARIL and ADVIL ALLERGY SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISTARIL is: Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.. The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISTARIL and ADVIL ALLERGY SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISTARIL is classified as Category C. First trimester: Limited human data; animal studies suggest no major teratogenic risk; fetal harm cannot be ruled out. Second and third trimesters: Hydroxyzine may cause neonatal w. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.